Editas Medicine, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $470.0M
- Price
- $2.69
- % Change (Daily % change from the live per-ticker quote feed.)
- -7.88%
- Volume
- 5.2M
About
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Quick stats
Shares outstanding153.6M
Computed float148.8M
Float / shares96.9%
Cash runway (months)18.6
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001650664
AI Summary
AI-generated1/18
minorneutralexecutive change
Editas Medicine Reports Inducement Grants to New Chief Medical Officer
Editas Medicine disclosed an inducement stock option grant to Daniel Ory, M.D., its newly appointed Chief Medical Officer, approved under Nasdaq Listing Rule 5635(c)(4).
The award covers up to 950,000 shares at an exercise price of $3.03, set at EDIT's Nasdaq closing price on the date of grant.
The options vest over four years, with 25% vesting on the 15th day of the month following the first anniversary of Dr. Ory's start date and the remainder vesting ratably each month.
The release is routine onboarding equity rather than a strategic disclosure; the grant's modest size implies limited dilution, though the $3.03 strike underscores the depressed share price of this clinical-stage gene-editing company.
Red flags
- exercise price of $3.03 equals the grant-date close, reflecting a depressed share price for a clinical-stage gene-editing company
- new 950,000-share option grant adds modest potential dilution